Kia unveils battery-powered EV5
The 'family-oriented' all-electric EV5 comes with a 'bold' SUV exterior, a spacious minimalist interior with panoramic display that integrates a 12.3-inch cluster, 12.3-inch infotainment screen, and a dedicated 5-inch climate control panel.
The EV5 is driven by a 160 kW electric motor and comes with a choice of two batteries: 60 kWh for the Base-Line model and 81 kWh for the GT-Line. The Base-Line model has a range of 530 km on a single charge, while the GT model has a range of 505 km.
The EV5 range will be rolled out in South Korea and Europe in the second half of 2025, with sales in North America scheduled to start in early 2026.
Kia president and CEO, Ho Sung Song, said in a statement: 'The EV5 represents a significant step in Kia's shift toward electrified mobility. This vehicle was developed not only to expand our electric lineup, but to make EV ownership more practical and appealing to a broader range of drivers. With the EV5's global launch, we are reinforcing our presence in key markets including Korea, Europe and North America, and continuing our commitment to making sustainable mobility more accessible worldwide.'
"Kia unveils battery-powered EV5" was originally created and published by Just Auto, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Strong Earnings and Trade Deal Optimism Bolster Stocks
The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.02%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.56%. September E-mini S&P futures (ESU25) are up +0.15%, and September E-mini Nasdaq futures (NQU25) are up +0.50%. Stock indexes today are mostly moving higher, with the S&P 500 and Nasdaq 100 posting new record highs. Strong quarterly corporate earnings results and positive trade news are supporting gains in stocks. Commerce Secretary Lutnick said a 90-day extension of a trade truce with China was a likely outcome with negotiations between the two countries underway in Stockholm. Stocks also found some support from today's US economic news that showed the Jun advance goods trade deficit unexpectedly shrank to -$86.0 billion versus expectations of a widening to -$98.0 billion, a positive factor for Q2 GDP. More News from Barchart Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Dear Microsoft Stock Fans, Mark Your Calendars for Aug. 1 Is Lucid Motors Stock a Buy, Sell, or Hold for July 2025? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! M&A activity is also supportive of stocks as Union Pacific agreed to acquire Norfolk Southern for about $85 billion, or around $320 a share. Also, Baker Hughes acquired Chart Industries for $9.6 billion, or about $210 a share. Weighing on the Dow Jones Industrials is a -6% fall in Merck & Co after it said it will extend its shipment pause of the Gardasil vaccine to China through at least the end of the year, citing soft demand. Also, UnitedHealth Group is down more than -5% after reporting weaker-than-expected Q2 adjusted EPS and forecasting full-year adjusted EPS below consensus. The US May S&P CoreLogic composite-20 home price index rose +2.79% y/y, weaker than expectations of +2.91% and the smallest pace of increase in 1.75 years. The markets this week will focus on any news of new trade deals before Friday's deadline. Later today, the Jun JOLTS job openings are expected to decline by -269,000 to 7.50 million. Also, the Conference Board's US Jul consumer confidence index is expected to climb by +3.0 to 96.0. In addition, the 2-day FOMC meeting begins on Tuesday, and the Fed is expected to keep the fed funds target range unchanged at 4.25% to 4.50% when the meeting ends on Wednesday. Also on Wednesday, the Jul ADP employment change is expected to climb by +80,000. Finally, on Wednesday, Q2 GDP is expected to expand by +2.4% (q/q annualized) and the Q2 core PCE price index is expected to ease to +2.3% from +3.5% in Q1. On Thursday, initial weekly unemployment claims are expected to rise by 6,000 to 223,000, and the Q2 employment cost index is expected to increase by 0.8%. Also, Jun personal spending is expected to climb +0.4% m/m and Jun personal income is expected to rise +0.3% m/m. In addition, the Jun core PCE price index, the Fed's preferred inflation gauge, is expected to climb +0.3% m/m and +2.7% y/y. Finally, on Thursday, the Jul MNI Chicago PMI is expected to increase by +1.6 to 42.0. On Friday, Jul nonfarm payrolls are expected to increase by +109,000 and the Jul unemployment rate is expected to rise by +0.1 to 4.2%. Also, Jul average hourly earnings are expected +0.3% m/m and +3.8% y/y. In addition, the Jul ISM manufacturing index is expected to increase by +0.2 to 49.5. Finally, the University of Michigan Jul consumer sentiment index is expected to be unrevised at 61.8. The markets are awaiting President Trump's August 1 deadline for trade deals to avoid high tariffs. On July 16, Mr. Trump announced that he intends to send a tariff letter to more than 150 countries, notifying them that their tariff rates could be 10% or 15%, effective August 1. As an update, Mr. Trump last Wednesday said, 'We'll have a straight, simple tariff of anywhere between 15% and 50%,' an indication that the floor for tariffs is rising and suggesting that he would not go below 15%. Federal funds futures prices are discounting the chances for a -25 bp rate cut at 3% at the Tue/Wed FOMC meeting and 66% at the following meeting on September 16-17. This week kicks off the earnings season's busiest week, with 38% of the stocks in the S&P 500 reporting quarterly earnings, double the amount reported last week. The earnings results of Magnificent Seven members will be front and center, with Microsoft and Meta Platforms reporting on Wednesday and Apple and reporting on Thursday. Early results show that S&P 500 earnings are on track to rise +4.5% for the second quarter, better than the pre-season expectations of +2.8% y/y, according to Bloomberg Intelligence. With about a third of S&P 500 firms having reported, around 82% exceeded profit estimates. Overseas stock markets today are mixed. The Euro Stoxx 50 is up +1.16%. China's Shanghai Composite closed up +0.33%. Japan's Nikkei Stock 225 closed down -0.79%. Interest Rates September 10-year T-notes (ZNU25) today are up +4 ticks. The 10-year T-note yield is down -1.4 bp to 4.396%. T-notes are moving higher today on some short covering ahead of the start of the 2-day FOMC meeting. Limiting gains in T-notes are supply pressures, as the Treasury will auction $30 billion of 2-year floating-rate notes and $44 billion of 7-year T-notes later today. Also, strength in stocks today has reduced safe-haven demand for T-notes. European government bond yields today are moving higher. The 10-year German bund yield is up +1.6 bp to 2.705%. The 10-year UK gilt yield rose to a 1-week high of 4.681% and is up +0.4 bp to 4.651%. The ECB Jun 1-year inflation expectations eased to +2.6% from 2.8% in May. The ECB Jun 3-year inflation expectations were unchanged from May at +2.4%. Swaps are discounting the chances at 15% for a -25 bp rate cut by the ECB at the September 11 policy meeting. US Stock Movers The strength in chip stocks today is providing support to the broader market. Advanced Micro Devices (AMD), On Semiconductor Corp (ON), and Marvell Technology (MRVL) are up more than +2%. Also, Broadcom (AVGO), Nvidia (NVDA), Lam Research (LRCX), GlobalFoundries (GFS), KLA Corp (KLAC), and NXP Semiconductors NV (NXPI) closed up more than +1%. Sarepta Therapeutics (SRPT) is up more than +27% after US regulators recommended that patients who can walk be allowed to take the company's gene therapy Elevidys again. Amkor Technology (AMKR) is up more than +21% after reporting Q2 net sales of $1.51 billion, better than the consensus of $1.42 billion, and forecast Q3 net sales of $1.88 billion-$1.98 billion, well above the consensus of $1.76 billion. Chart Industries (GTLS) is up more than +16% after Baker Hughes acquired the company for $13.6 billion, or about $210 a share. Cadence Design Systems (CDNS) is up more than +9% to lead gainers in the S&P 500 and Nasdaq 100 after reporting Q2 revenue of $1.28 billion, above the consensus of $1.25 billion, and raised its full-year revenue forecast to $5.21 billion-$5.27 billion from a previous estimate of $5.15 billion-$5.23 billion, stronger than the consensus of $5.20 billion. Corning (GLW) is up more than +7% after reporting Q2 core EPS of 60 cents, above the consensus of 57 cents, and forecasting Q3 core EPS of 63 cents-67 cents, better than the consensus of 62 cents. CBRE Group (CBRE) is up more than +7% after reporting Q2 revenue of $9.75 billion, stronger than the consensus of $9.43 billion, and raising its full-year core EPS estimate to $6.10-$6.20 from a previous estimate of $5.80-$6.10. Brown & Brown (BRO) is down more than -9% to lead losers in the S&P 500 after reporting Q2 organic revenue rose +3.60%, weaker than the consensus of +5.63%. Whirlpool (WHR) is down more than -8% after reporting Q2 net sales of $3.77 billion, below the consensus of $3.85 billion, and cutting its full-year EPS forecast to $6.00-$8.00 from a previous estimate of about $10, well below the consensus of $8.78. Stanley Black & Decker (SWK) is down more than -8% after reporting Q2 net sales of $3.95 billion, weaker than the consensus of $4.00 billion. Carrier Global (CARR) is down more than -8% after forecasting full-year free cash flow of $2.4 billion to $2.6 billion, the midpoint below the consensus of $2.55 billion. Royal Caribbean Cruises Ltd (RCL) is down more than -8% after forecasting Q3 adjusted EPS of $5.55-$5.65, weaker than the consensus of $5.84. United Parcel Service (UPS) is down more than -7% after it pulled guidance for the year, citing 'current macro-economic uncertainty.' Merck & Co. (MRK) is down more than -6% to lead losers in the Dow Jones Industrials after it said it will extend its shipment pause of the Gardasil vaccine to China through at least the end of the year, citing soft demand. UnitedHealth Group (UNH) is down more than -5% after reporting Q2 adjusted EPS of $4.08, weaker than the consensus of $4.59, and forecasting full-year adjusted EPS of at least $16, well below the consensus of $20.40. Earnings Reports (7/29/2025) American Tower Corp (AMT), Arch Capital Group Ltd (ACGL), Boeing Co/The (BA), Booking Holdings Inc (BKNG), BXP Inc (BXP), Caesars Entertainment Inc (CZR), Carrier Global Corp (CARR), CBRE Group Inc (CBRE), Corning Inc (GLW), DTE Energy Co (DTE), Ecolab Inc (ECL), Electronic Arts Inc (EA), Essex Property Trust Inc (ESS), Expand Energy Corp (EXE), Hubbell Inc (HUBB), Incyte Corp (INCY), Johnson Controls International (JCI), Merck & Co Inc (MRK), Mondelez International Inc (MDLZ), Norfolk Southern Corp (NSC), PayPal Holdings Inc (PYPL), PPG Industries Inc (PPG), Procter & Gamble Co/The (PG), Regency Centers Corp (REG), Republic Services Inc (RSG), Royal Caribbean Cruises Ltd (RCL), Seagate Technology Holdings PL (STX), Stanley Black & Decker Inc (SWK), Starbucks Corp (SBUX), Sysco Corp (SYY), Teradyne Inc (TER), United Parcel Service Inc (UPS), UnitedHealth Group Inc (UNH), Visa Inc (V). On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO's Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies. The objective of the new partnership with Valneva is to establish phase II supply relying on the ability of AGC Biologics' Heidelberg site to guide complex molecules through clinical stages. Valneva and LimmaTech announced the launch of a Phase 2 infant study in April, and a Phase 2b Human Challenge Study (CHIM) in November 2024. Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world. "Our site's unique ability to handle complex molecules and multi-valent assets can help this potentially life-saving program reach its next clinical milestone," said Dieter Kramer, Senior Vice President and General Manager, AGC Biologics Heidelberg. "We appreciate Valneva entrusting our team of experts with this challenge and are honored to contribute to efforts that aim to prevent millions of deadly infections in the future." AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The site has produced biologics products for 40 years. It offers developers freedom-to-operate strain development, proven experience with different bacterial and yeast systems, proprietary plasmid DNA (pDNA) and messenger RNA (mRNA) platforms, large-scale tanks for late-phase protein refolding, the ability to take on early-phase and fast track projects, and late-phase and commercial expertise. To learn more about the microbial system-based biologics, pDNA and mRNA manufacturing site in Heidelberg, visit For more information on AGC Biologics' global CDMO services across all modalities, go to About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Yahoo
2 hours ago
- Yahoo
Corn Easing on Tuesday Morning Despite Rating Slip
Corn price action is down fractionally to a penny so far on Tuesday. Futures closed out the Monday session holding to their bearish sentiment from earlier in the day. Contracts were down 5 to 6 cents at the close. Preliminary open interest showed new selling interest, up 6,950 contracts. The CmdtyView national average new crop Cash Corn price was down 5 1/4 cents at $3.71 3/4. Crop Progress data indicated 76% of the US corn crop was silking as of 7/27, 1 point back of the 5-year average. The crop was 26% in the dough stage, vs. the 24% average. Condition ratings were down 1 point at 73% gd/ex and 384 on the Brugler500 index. More News from Barchart Coffee Prices Sharply Higher on Weather and Tariff Concerns in Brazil Adverse Brazilian Weather and Tariff Concerns Boost Coffee Prices Corn Bulls Are Bending, Not Breaking: What to Watch in Grain Futures This Week Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. USDA tallied corn export shipments at 1.522 MMT (59.93 mbu) during the week ending on July 24. That was up 54.55% from last week and 42.16% above the same week last year. Of that total, 610,316 MT was headed to Japan, with 460,381 MT on its way to Mexico. Marketing year exports have totaled 60.34 MMT (2.376 bbu), which is 29.25% above the same period last year. A South Korean importer purchased a total of 132,000 MT of corn in a tender overnight. A Taiwan importer also issued a tender for 65,000 MT of corn. Sep 25 Corn closed at $3.93 3/4, down 5 3/4 cents, currently down 1 cent Nearby Cash was $3.78 1/2, down 6 1/4 cents, Dec 25 Corn closed at $4.14, down 5 cents, currently down 3/4 cent Mar 26 Corn closed at $4.31 1/4, down 5 1/4 cents, currently down 1 cent New Crop Cash was $3.71 5/8, down 5 1/4 cents, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
